Nolato gets the VHP permit, reiterates Q4 guidance Nolato has announced that it has now been granted...
We attended Rovio’s Q4 mid-quarter meeting on Friday hosted by IR Timo Rahkonen.
Sivers announced its largest development agreement to date, worth cSEK170m.
Redeye initiates coverage of Newbury Pharmaceuticals, a hybrid pharmaceutical company focusing on pr...
Upplagt för bra avslutning på 2022 Devyser har fortsatt visa hög tillväxt under hela 2022.
Tecknar avtal med XPENG North Projects, ett dotterbolag till Transtema, har ingått ett exklusivt avt...
Q3 Nettoomsättningen kom in på 0,9 mkr (0,3) och rörelseresultatet blev -3,7 mkr (-3,0) under det tr...
Redeye states that the first part of the IPR process for patent 879 has favoured Neonode.
Endomines seeks to raise gross proceeds of EUR 13m (SEK 141m), the proceedings are used especially f...
IT-bolaget Qlosr:s intäkter uppgick till 125,3 (32,7) miljoner kronor under det tredje kvartalet 202...
Redeye keeps its valuation range and base case unchanged despite a lowered revenue and EBIT expectat...
Redeye comments on Careium’s press release of the appointment of Christian Walén as the new CEO and ...
Scandion Oncology has announced the appointment of Francois Martelet, MD, as CEO, effective from 2 J...
Duearity AB (”Duearity” eller ”Bolaget”) erbjuder unika medicinsktekniska lösningar för lindring och...
CEO Juha Gröhn will retire on 31 May 2023. New CEO will be Kai Gyllström who will start as of 1 June...
Organisk tillväxt i underkant Under det tredje kvartalet 2022 uppvisade SMG en nettoomsättning om 14...
Summary of Operating Activities During Q3-22, the revenue amounted to SEK 0.
Redeye initiates coverage of Norse Impact, a leading distributor in the Nordic e-commerce segment fo...
Redeye comments on Flexion's newly announced directed share issue.
Q3'22 results overview Eolus had net sales of SEK 111m, below our expectations of SEK 502m, as we ha...
